Barclays PLC Buys 169,756 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Barclays PLC boosted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 134.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 296,384 shares of the company’s stock after purchasing an additional 169,756 shares during the quarter. Barclays PLC’s holdings in Amneal Pharmaceuticals were worth $2,466,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in AMRX. Profund Advisors LLC increased its stake in shares of Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after acquiring an additional 1,680 shares during the last quarter. Rothschild Investment LLC bought a new stake in Amneal Pharmaceuticals in the second quarter valued at approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Amneal Pharmaceuticals by 13.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after purchasing an additional 4,115 shares during the period. Gladius Capital Management LP bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth $37,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $42,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Insider Activity

In related news, SVP Jason B. Daly sold 43,657 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the transaction, the senior vice president now owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. This trade represents a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 17.46% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock opened at $7.85 on Thursday. Amneal Pharmaceuticals, Inc. has a 52-week low of $5.01 and a 52-week high of $9.48. The business’s 50 day simple moving average is $8.38 and its 200 day simple moving average is $7.96. The firm has a market cap of $2.43 billion, a PE ratio of -11.54 and a beta of 1.12.

Wall Street Analyst Weigh In

Several research analysts have weighed in on AMRX shares. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Piper Sandler lifted their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Truist Financial raised their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.